DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma
Our findings underscore the role of DNAJ-PKAc in rewiring signalling networks and highlight valuable clinical implications for PLK1-targeted therapies for FLC.
Authors
- Taranjit S. Gujral (ORCID: https://orcid.org/0000-0002-4453-3031)
- Sean M. Ronnekleiv‐Kelly (ORCID: https://orcid.org/0000-0001-6664-996X)
- Kimberly J. Riehle (ORCID: https://orcid.org/0000-0003-4742-0910)
- Songli Zhu (ORCID: https://orcid.org/0000-0001-8560-5444)
- Luísa T. Ferreira (ORCID: https://orcid.org/0000-0002-0868-3964)
- Raymond S. Yeung (ORCID: https://orcid.org/0000-0001-5090-3046)
- Manabu Nukaya (ORCID: https://orcid.org/0000-0002-6204-0978)
- John D. Scott (ORCID: https://orcid.org/0000-0002-0367-8146)
- Marina Chan
Institutions
- University of Wisconsin–Madison (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Gut
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1136/gutjnl-2024-334274
- Citations
- 6
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 6.91
Funders
- U.S. Department of Defense
- Fibrolamellar Cancer Foundation